Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
94 hedge funds and large institutions have $259M invested in Achillion Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 15 closing their positions.
787% more call options, than puts
Call options by funds: $27.6M | Put options by funds: $3.12M
1% more funds holding
Funds holding: 93 → 94 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $263M → $259M (-$3.9M)
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.04M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.54M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.86M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.5M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$785K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$3.06M |
| 2 |
First Eagle Investment Management
New York
|
-$1.99M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.92M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.59M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$1.4M |
ACHN Hedge Fund Activity: Q1 2014 in Review
94 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q1 2014, worth a combined $259M — down 1.5% from $263M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ACHN positions and 15 closed out — a net gain of 1 holder — while 30 added to existing stakes and 32 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $3.04M. The largest seller was Visium Asset Management, exiting entirely with an estimated $3.06M sold.
- 94 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q1 2014, up from 93 in Q4 2013.
- Funds reported $259M of Achillion Pharmaceuticals stock for Q1 2014, down 1.5% quarter-over-quarter.
- 16 funds opened new Achillion Pharmaceuticals positions in Q1 2014 and 15 closed out, a net change of +1 holder.
- The largest Achillion Pharmaceuticals buyer in Q1 2014 was Adage Capital Partners, an estimated $3.04M added.
- The largest Achillion Pharmaceuticals seller in Q1 2014 was Visium Asset Management, an estimated $3.06M sold.
Based on aggregated 13F filings for Q1 2014.